Immunology

Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs

March 29th 2024

By Skylar Jeremias

Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.

Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD

March 23rd 2024

By Deana Ferreri, PhD

Article

A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.

AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars

March 20th 2024

By Skylar Jeremias

Article

Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.

Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake

March 18th 2024

By Skylar Jeremias

Article

Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.

Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars

March 17th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.

Adalimumab Expenditures in Countries With and Without Available Biosimilars

March 16th 2024

By Deana Ferreri, PhD

Article

A recent study used difference-in-difference analysis to assess adalimumab sales volumes and expenditures in 6 countries with and 8 countries without available biosimilar adalimumab products.

Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics

March 14th 2024

By Skylar Jeremias

Article

Posters from Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit (AMCCBS) and the American Academy of Dermatology (AAD) highlight the benefits of incorporating biosimilars into electronic medical records and the biggest barriers for home injection of biologics.

Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5

March 9th 2024

By Deana Ferreri, PhD

Article

The adalimumab biosimilar SB5 was reported to be as safe and effective as the reference product in a review of randomized controlled trials and real-world studies on immune-mediated inflammatory diseases.

FDA Green Lights Second Tocilizumab Biosimilar

March 7th 2024

By Skylar Jeremias

Article

The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.

Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo

March 6th 2024

By Skylar Jeremias

Article

Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.